|
KMID : 1103920140200030274
|
|
Korean Journal of Hepatology
2014 Volume.20 No. 3 p.274 ~ p.282
|
|
|
Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudineadefovir combination therapy in patients with lamivudine- resistant chronic hepatitis B
|
|
Kim Jeong-Han
Moon Hee-Won
Ko Soon-Young
Choe Won-Hyeok
Kwon So-Young
|
|
|
Abstract
|
|
|
Background/Aims: Quantitation of hepatitis B surface antigen (HBsAg) is an increasingly popular method to determine the treatment response in chronic hepatitis B (CHB) patients. The clinical value of HBsAg level measurement during rescue therapy for lamivudine (LMV)-resistant CHB patients have not been evaluated to date. Therefore, this study investigated the correlation between HBsAg level and treatment response in LMV- resistant CHB patients treated with adefovir (ADV) add-on therapy.
Methods: LMV-resistant CHB patients treated with LMV-ADV combination therapy for over 2 years were included. HBsAg levels were measured at 6 month intervals until 1 year, and annually thereafter. Treatment response was assessed by determining the virological response (VR, undetectable HBV DNA levels) during treatment.
Results: Fifty patients were included, of which 40 showed a VR. HBsAg levels were not different significantly at baseline (4.0 vs. 3.6 Log10 IU/mL, p=0.072). However, the HBsAg level decreased after 6 months of treatment in patients with a VR and became different significantly between the groups thereafter (3.9 vs. 3.3 at 6 months, p=0.002; 3.8 vs. 3.2 at 1 year, p=0.004; 3.9 vs. 3.2 at 2 years, p=0.008; 3.7 vs. 3.1 at 3 years, p =0.020).
Conclusions: The HBsAg level at 6 months after treatment can help predict treatment response.
|
|
|
KEYWORD
|
|
|
Hepatitis B, Chronic, Hepatitis B surface antigen, Lamivudine, Adefovir, Resistance
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|
|